平均风险筛查等效年轻成人结肠镜检查结果:来自新罕布什尔州结肠镜登记处的数据
利用新罕布什尔州结肠镜登记处数据,将45-49岁「平均风险筛查等效」组与50-54岁及以上筛查结肠镜患者进行比较,发现45-49岁与50-54岁进展期肿瘤患病率相似,且进展期肿瘤风险从40岁开始增加。
要点
- 45-49岁与50-54岁组的进展期肿瘤患病率相似。
- 进展期肿瘤患病率从40-44岁组开始较<40岁组显著增加。
- 被认为低风险的诊断指征并不能预测进展期肿瘤。
核心结论
- 新罕布什尔州结肠镜登记处数据显示进展期肿瘤风险从40岁开始增加,45-49岁与50-54岁个体患病率相似,为优化预防和筛查起始年龄提供了临床有用证据。
- 这是一个复杂问题,涉及其他额外考虑,需要进一步解决。
研究设计与样本
- 使用新罕布什尔州结肠镜登记处数据,比较45-49岁「平均风险筛查等效」组与50-54岁及以上接受筛查结肠镜患者的进展期肿瘤患病率。
- 将50岁以上有诊断指征(腹痛和便秘)预期进展期肿瘤患病率类似筛查低风险的患者与筛查指征患者合并为「平均风险筛查等效」组。
- 排除高风险指征(如出血和贫血)、监测检查、结直肠癌一级亲属家族史、检查不完整和肠道准备差的患者。
- 样本量n=40,812。
主要发现
- 进展期肿瘤患病率:<40岁1.1%,40-44岁3.0%,45-49岁3.7%,50-54岁3.6%,55-59岁5.1%,60岁以上6.7%(所有组间P < 0.0001)。
- 45-49岁与50-54岁年龄组的进展期肿瘤和临床显著锯齿状息肉患病率相似。
- 40-44岁组进展期肿瘤患病率较<40岁组显著增加。
- 调整分析证实了这些结果。
- 被认为低风险的诊断指征不能预测进展期肿瘤。
关键数值与推荐
- 进展期肿瘤定义:≥1 cm、绒毛状、高级别异型增生和结直肠癌。
- 临床显著锯齿状息肉定义:大(≥1 cm)增生性息肉、无蒂锯齿状息肉、传统锯齿状腺瘤和近端≥5 mm增生性息肉。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Data are needed to further inform the American Cancer Society recommendation to begin colorectal cancer (CRC) screening at age 45. We used the New Hampshire Colonoscopy Registry to compare the prevalence of advanced neoplasia (AN) in an "average-risk screening equivalent" group aged 45-49 years with patients aged 50-54 years and older receiving screening colonoscopy. METHODS: Colonoscopies in adults older than 50 years of age usually have diagnostic indications of varying clinical significance. We combined patients older than 50 years with diagnostic indications (abdominal pain and constipation) expected to yield AN prevalence similar to screening low AN risk and those with a screening indication to form an "average-risk screening equivalent" group. We excluded high-risk indications (e.g., bleeding and anemia), surveillance examinations, and patients with a first-degree family history of CRC, incomplete examinations, and poor bowel preparation. We calculated prevalence/adjusted risks for AN (≥1 cm, villous, high-grade dysplasia, and CRC) and clinically significant serrated polyps (large [≥1 cm] hyperplastic polyps, sessile serrated polyp, traditional serrated adenomas, and proximal hyperplastic polyp ≥ 5 mm). RESULTS: In our sample (n = 40,812), AN prevalence was as follows: <40 years (1.1%), 40-44 years (3.0%), 45-49 years (3.7%), 50-54 years (3.6%), 55-59 years (5.1%), and 60+ years (6.7%) (P < 0.0001 across all groups). The prevalence of both AN and clinically significant serrated polyp was similar in the 45-49 and 50-54 years' age groups. Furthermore, the prevalence of AN increased significantly in the 40-44 group as compared to that in the <40 years group. Adjusted analyses confirmed these results. The diagnostic indications considered to have low risk were not predictive of AN. DISCUSSION: New Hampshire Colonoscopy Registry data, demonstrating an increase in AN risk starting at age 40 and a similar prevalence for individuals aged 45-49 and those ages 50-54, provide clinically useful evidence for optimization of prevention and the age to start screening. However, this is a complex issue involving additional considerations that will need to be addressed.
引用
- Butterly LF, Siegel RL, Fedewa S, et al. Colonoscopy Outcomes in Average-Risk Screening Equivalent Young Adults: Data From the New Hampshire Colonoscopy Registry. Am J Gastroenterol. 2021. PMID: 32833734. doi:10.14309/ajg.0000000000000820
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。